Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have issued a strong buy rating on the company.

A number of brokerages have recently commented on BAYRY. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Zacks Research cut Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 24th. DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 9th. Finally, Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th.

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock opened at $11.11 on Friday. The firm’s fifty day simple moving average is $11.46 and its 200-day simple moving average is $10.76. The stock has a market capitalization of $43.66 billion, a price-to-earnings ratio of -10.01 and a beta of 0.62. Bayer Aktiengesellschaft has a 12 month low of $6.20 and a 12 month high of $14.85. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. The firm had revenue of $13.24 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, equities analysts forecast that Bayer Aktiengesellschaft will post 1.2 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.